Role of advanced glycation end products in diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 3, 2003, Pages

  Forbes, Josephine M ^a   Cooper, Mark E ^a   Oldfield, Matthew D ^a   Thomas, Merlin C ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; CAPTOPRIL; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GLUCOSE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; CELL INTERACTION; COLLAGEN SYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FIBROGENESIS; GENETIC TRANSCRIPTION; GLOMERULUS; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY TUBULE EPITHELIUM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 0041364626     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001
2. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001
3. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, Jerums G: Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40: 1141-1151, 1997
4. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91: 11704-11708, 1994
5. Bai P, Phua K, Hardt T, Cemadas M, Brodsky B: Glycation alters collagen fibril organization. Connect Tissue Res 28: 1-12, 1992
6. Silbiger S, Crowley S, Shan Z, Brownlee M, Satriano J, Schlondorff D: Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int 43: 853-864, 1993
7. Raabe HM, Hopner JH, Notbohm H, Sinnecker GH, Kruse K, Muller PK: Biochemical and biophysical alterations of the 7S and NC1 domain of collagen IV from human diabetic kidneys. Diabetologia 41: 1073-1079, 1998
8. Mott JD, Khalifah RG, Nagase H, Shield CF 3rd, Hudson JK, Hudson BG: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52: 1302-1312, 1997
9. Nyengaard JR, Chang K, Berhorst S, Reiser KM, Williamson JR, Tilton RG: Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes 46: 94-106, 1997
10. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T: The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43: 660-664, 2000
11. Forbes JM, Thallas V, Thomas MC, Jerums G, Cooper ME: Renoprotection is afforded by the advanced glycation end product (AGE) cross-link breaker, ALT-711. FASEB J 2003, in press
12. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC: Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 272: 27966-27970, 1997
13. Tarsio JF, Wigness B, Rhode TD, Rupp WM, Buchwald H, Furcht LT: Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 34: 477-484, 1985
14. Charonis AS, Tsilbary EC: Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes 41: 49-51, 1992
15. Walton HA, Byrne J, Robinson GB: Studies of the permeation properties of glomerular basement membrane: Cross-linking renders glomerular basement membrane permeable to protein. Biochim Biophys Acta 1138: 173-183, 1992
16. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME: Aminoguanidine ameliorates over-expression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12: 2098-2107, 2001
17. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS: Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med 138: 59-68, 2001
18. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91: 9436-9440, 1994
19. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY: Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 81: 102-113, 2001
20. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108: 1853-1863, 2001
21. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11: 25-38, 2000
22. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143: 4907-4915, 2002
23. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG: Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142: 1760-1769, 2001
24. Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12: 25-29, 2003
25. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY: Advanced glycation end products activate Smad signaling via TGF-beta-dependent and -independent mechanisms: implications for diabetic renal and vascular disease. FASEB J Express 1096/fj.02-1117fje; published online April 22, 2003
26. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F, Kalluri R: Renal fibrosis: Collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159: 1313-1321, 2001
27. Zaoui P, Cantin JF, Alimardani-Bessette M, Monier F, Halimi S, Morel F, Cordonnier D: Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab 26: 25-29, 2000
28. McLennan SV, Martell SK, Yue DK: Effects of mesangium glycation on matrix metalloproteinase activities: Possible role in diabetic nephropathy. Diabetes 51: 2612-2618, 2002
29. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 63: 172-178, 2003
30. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282, 2002
31. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 13: 2478-2487, 2002
32. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 48: 1-9, 1999
33. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001
34. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61: 186-194, 2002
35. Yim MB, Yim HS, Lee C, Kang SO, Chock PB: Protein glycation: Creation of catalytic sites for free radical generation. Ann N Y Acad Sci 928: 48-53, 2001
36. Lal MA, Brismar H, Eklof AC, Aperia A: Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 61: 2006-2014, 2002
37. Li JF, Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272: 16498-16506, 1997
38. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49: 87-93, 2000
39. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-1927, 2002
40. Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44: 1957-1972, 2001